Considering the increase association of IDO1 expression and HPV-induced malignancies, incorporation of two immunometabolic adjuvants, melatonin and IDO1 inhibitors, to an anti-cancer vaccine resulted in enhanced in vivo antitumor effectiveness without visually noticeable side effects usually observed with other anti-cancer treatments. This evidence concerns the gene IDO1 and cancer.